MCMEG: Intercomparison exercise on prostate radiotherapy dose assessment

Due to the reported high incidence of thyroid cancer induced by radiotherapy, dose assessment is significant to prevent thyroid late effects. Thyroid dosimetry can be evaluated either by entrance skin dose (ESD) measured with thermoluminescent dosimeter (TLD) arrays or by absorbed dose (AD) computed with treatment planning system. However, their correlation has hardly been reported in any publications. Moreover, the reported measurement procedures for thyroid ESD are usually inefficient. This study aims to provide a fast model for efficient acquisition of thyroid ESD and analyze the coherent relationship between ESD and AD. We conducted the study on the China radiation anthropomorphic phantom with intentionally delineated cancers, irradiated by a Varian 23EX linac. We have measured the ESD with TLD at 5 different points, while computed AD with the Oncentra Masterplan TPS. The ESD at the middle gorge of thyroid has exhibited significant linear correlation with those measured at other points. Furthermore, a regressive model has been proposed to predict thyroid AD from ESD. Consequently, it is recommended to only measure the ESD at the middle gorge of thyroid for an efficient dose assessment. The validity of the regressive model to predict thyroid AD from ESD has also been demonstrated.

Download Full-text

Assessment of an ultrasound bladder scanner in prostate radiotherapy: A validation study and analysis of bladder filling variability

Ultrasound ◽

10.1177/1742271x21995217 ◽

2021 ◽

pp. 1742271X2199521

Author(s):

L Smith ◽

J Gittins ◽

KV Ramnarine ◽

EML Chung

Keyword(s):

Bladder Volume ◽

Prostate Radiotherapy ◽

Dose Volume ◽

Quantitative Basis ◽

Volume Measurements ◽

Pre Treatment ◽

Dose Constraints ◽

Radiotherapy Dose ◽

Volume Estimates ◽

Radiotherapy Treatment

Introduction During prostate radiotherapy treatment, it is important to ensure the position of the bladder and prostate is consistent between treatments. The aim of this study was to provide a quantitative basis for incorporating ultrasound bladder volume estimates into local practice for prostate radiotherapy. Methods Agreement between bladder volume estimates obtained using computed tomography (CT) and ultrasound was assessed. Analysis of bladder volumes between planning and treatment scans was used to quantify expected variations in bladder volume over the course of radiotherapy. Dose–volume statistics were estimated and compared to planned dose constraints to propose a target bladder volume and tolerance. Results Bladder volume measurements were obtained from 19 radiotherapy patients using ultrasound and CT. Ultrasound underestimated bladder volume compared to CT with a mean bias of –28 ± 30 ml. Pre-treatment (planning) bladder volumes varied from 71 to 383 ml with a mean of 200 ml. Treatment bladder volumes reduced by more than half in 9% of patients during the course of their treatment, potentially leading to a 30% increase in mean bladder dose. Patients with pre-treatment bladder volumes < 200 ml were most likely to exhibit differences in bladder volume, resulting in ‘out of tolerance’ increases in dose. Conclusions A pragmatic individualised drinking protocol, aimed at achieving a minimum ultrasound bladder volume of 200 ml at planning CT, may be beneficial to reproducibility in radiotherapy treatment. Ultrasound measurements prior to treatment should ideally confirm that bladder volume is at least half the volume measured at planning.

Download Full-text